Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875043 | 0.77 | TDP1 (0.39) | ALDH1A1TSHRTDP1ABCB1ABCC1 | |
| SCHEMBL28412955 | 0.76 | TDP1 (0.41) | CA12CA1CA2CA4CA5A | |
| SCHEMBL464892 | 0.75 | CA12 (0.41) | CA12CA1CA2CA4CA5A | |
| SCHEMBL7154403 | 0.69 | ALDH1A1 (0.38) | CA12CA1CA2CA4CA5A | |
| SCHEMBL28045237 | 0.69 | RECQL (0.46) | CA12CA1CA2CA4CA5A | |
| SCHEMBL2057427 | 0.69 | ABCB1 (0.43) | CA12CA1CA2CA4CA5A | |
| Ammonia Solution, Strong SCHEMBL30339155 | 0.68 | ABCB1 (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL10980604 | 0.68 | HSP90AA1 (0.45) | ALDH1A1HSP90AA1EPHX2 | |
| SCHEMBL896258 | 0.68 | HSP90AA1 (0.43) | ALDH1A1TSHRHSP90AA1EPHX2 | |
| SCHEMBL8579302 | 0.68 | HSP90AA1 (0.43) | ALDH1A1TSHRHSP90AA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150037271-A1 | Methods for Fixing Hair and Skin | LIQWD, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8884031-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778877-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-8609679-B2 | 2,4-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8207353-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8188137-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799339-B2 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | CA12 1126/4885CA1 2195/4885CA2 3187/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CA12 2068/4885CA1 3888/4885CA2 3859/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CA12 4510/4885CA1 4409/4885CA2 2659/4885 |
| US-20150037271-A1 | Methods for Fixing Hair and Skin | CUTA, SUCLG1, TST | CA12 2214/4885CA1 859/4885CA2 1286/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | CA12 1172/4885CA1 715/4885CA2 1865/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CA12 1714/4885CA1 4107/4885CA2 3325/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CA12 2068/4885CA1 3888/4885CA2 3859/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CA12 2068/4885CA1 3888/4885CA2 3859/4885 |
| US-20150232490-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CA12 1877/4885CA1 2999/4885CA2 3556/4885 |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CA12 1877/4885CA1 2999/4885CA2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.